The Effect of Borderline Pulmonary Hypertension on Survival in Chronic Lung Disease

Lucilla Piccari(Hospital Del Mar), Stephen J. Wort(Royal Brompton Hospital), Federica Meloni(University of Pavia), Monica Rizzo(Istituti di Ricovero e Cura a Carattere Scientifico), Laura Price(Royal Brompton Hospital), Lavinia Martino(Istituti di Ricovero e Cura a Carattere Scientifico), Elena Salvaterra(University of Pavia), Laura Scelsi(University of Pavia), Manuel López‐Meseguer(Vall d'Hebron Hospital Universitari), Isabel Blanco(Centre for Biomedical Network Research on Rare Diseases), Adriana Callari(Istituti di Ricovero e Cura a Carattere Scientifico), Virginia Pérez González(Hospital Universitario 12 De Octubre), Fabio Tuzzolino(Istituti di Ricovero e Cura a Carattere Scientifico), Colm McCabe(Royal Brompton Hospital), Diego A. Rodríguez(Universitat Pompeu Fabra), Patrizio Vitulo(European Society of Hypertension), on behalf of the REHAR Registry Investigators
Respiration
January 1, 2022
Cited by 50Open Access
Full Text

Abstract

<b><i>Background:</i></b> The impact of the new “borderline” hemodynamic class for pulmonary hypertension (PH) (mean pulmonary artery pressure [mPAP], 21–24 mm Hg and pulmonary vascular resistance, [PVR], ≥3 wood units, [WU]) in chronic obstructive pulmonary disease (COPD) and interstitial lung disease (ILD) is unclear. <b><i>Objectives:</i></b> The aim of this study was to assess the effect of borderline PH (BLPH) on survival in COPD and ILD patients. <b><i>Method:</i></b> Survival was analyzed from retrospective data from 317 patients in 12 centers (Italy, Spain, UK) comparing four hemodynamic groups: the absence of PH (NoPH; mPAP <21 mm Hg or 21–24 mm Hg and PVR <3 WU), BLPH (mPAP 21–24 mm Hg and PVR ≥3 WU), mild-moderate PH (MPH; mPAP 25–35 mm Hg and cardiac index [CI] ≥2 L/min/m<sup>2</sup>), and severe PH (SPH; mPAP ≥35 mm Hg or mPAP ≥25 mm Hg and CI <2 L/min/m<sup>2</sup>). <b><i>Results:</i></b> BLPH affected 14% of patients; hemodynamic severity did not predict survival when COPD and ILD patients were analyzed together. However, survival in the ILD cohort for any PH level was worse than in NoPH (3-year survival: NoPH 58%, BLPH 32%, MPH 28%, SPH 33%, <i>p</i> = 0.002). In the COPD cohort, only SPH had reduced survival compared to the other groups (3-year survival: NoPH 82%, BLPH 86%, MPH 87%, SPH 57%, <i>p</i> = 0.005). The mortality risk correlated significantly with mPAP in ILD (hazard ratio [HR]: 2.776, 95% CI: 2.057–3.748, <i>p</i> < 0.001) and notably less in COPD patients (HR: 1.015, 95% CI: 1.003–1.027, <i>p</i> = 0.0146). <b><i>Conclusions:</i></b> In ILD, any level of PH portends worse survival, while in COPD, only SPH presents a worse outcome.


Related Papers

No related papers found

Powered by citation graph analysis